novel
coronaviru
wuhan
central
china
name
recent
caus
epidem
pneumonia
human
pose
huge
threat
global
public
health
date
led
confirm
case
death
china
accord
nation
health
commiss
peopl
republ
china
http
ennhcgov
cnindexhtml
case
also
document
grow
number
intern
locat
includ
unit
state
http
consequ
urgent
develop
effect
measur
control
novel
coronaviru
basi
pathogenesi
host
receptor
recognit
determin
viru
infect
time
letter
prepar
three
work
publish
explor
receptor
usag
work
zhengli
shi
et
al
shown
angiotensinconvert
enzym
receptor
sever
acut
respiratori
syndrom
coronaviru
sarscov
human
rhinolophu
sinicu
bat
civet
swine
mous
mediat
infect
vitro
detail
mechan
yet
determin
two
work
report
predict
human
usag
similar
way
sarscov
mainli
base
coronaviru
spike
glycoprotein
consid
fact
protein
mutat
gain
capabl
recogn
host
receptor
among
speci
still
lack
analys
receptor
usag
receptor
perspect
evolv
quickli
virus
firstli
perform
amino
acid
sequenc
align
differ
speci
includ
human
five
nonhuman
primat
gibbon
green
monkey
macaqu
orangutan
chimpanze
two
companion
anim
cat
dog
six
domest
anim
bovin
sheep
goat
swine
hors
chicken
three
wild
anim
ferret
civet
chines
horsesho
bat
two
rodent
mous
rat
align
clustal
w
show
share
high
sequenc
similar
except
chicken
data
shown
result
suggest
probabl
bat
origin
may
interact
chicken
subsequ
infect
consid
follow
analys
region
posit
demonstr
involv
interact
sarscov
protein
residu
posit
critic
therefor
took
close
comparison
region
residu
shown
fig
human
nonhuman
primat
share
ident
sequenc
region
residu
impli
nonhuman
primat
may
recogn
mediat
infect
result
nonhuman
primat
may
suscept
serv
anim
model
antivir
research
intermedi
host
crossspeci
transmiss
fig
residu
companion
domest
wild
anim
conserv
especi
critic
one
state
certain
one
variabl
exampl
conserv
probabl
form
salt
bridg
interestingli
chang
posit
observ
chang
suggest
steric
hindranc
electrostat
interfer
hostviru
interact
take
civet
exampl
chang
like
form
hydrogen
bond
instead
salt
bridg
addit
polar
side
chain
may
influenc
hydrophob
interact
origin
chang
may
result
lower
bind
affin
howev
addit
region
cover
residu
shown
involv
civet
bind
sarscov
enhanc
interact
consequ
ca
nt
preclud
exist
region
compens
residu
chang
residu
human
one
compaion
domest
wild
anim
may
favor
recognit
consist
recent
work
zhengli
shi
et
al
case
crossspeci
transmiss
close
contact
sick
asymptomat
companion
domest
wild
anim
cautiou
worker
livestock
farm
travel
wild
contrast
certain
signific
chang
occur
mous
andor
rat
compar
human
one
fig
mous
may
form
favor
interact
due
electrostat
hydrophil
characterist
importantli
chang
mous
rat
form
strong
salt
bridg
sinc
structur
inform
mous
rat
unavail
carri
homolog
model
use
human
pdb
code
templat
onlin
http
swissmodelexpasyorg
analys
fig
chang
mous
may
interfer
hydrophob
interact
origin
addit
chang
definit
affect
salt
bridg
format
electrostat
potenti
chang
rat
similar
effect
receptorviru
interact
fig
b
analys
partial
explain
mous
mediat
infect
report
zhengli
shi
et
al
assum
rodent
like
suscept
host
conclus
conduct
sequenc
structur
analys
angiotensinconvert
enzym
differ
speci
shed
light
crossspeci
receptor
usag
analys
rais
alert
potenti
interspeci
transmiss
propos
surveil
anim
popul
structur
studi
human
speci
complex
spike
protein
con
author
declar
conflict
interest
recent
letter
journal
infect
report
outbreak
novel
cornonaviru
dec
china
especi
hubei
provinc
novel
cornonaviru
may
origin
bat
name
world
health
organ
outbrok
wuhan
capit
hubei
provinc
spread
provinc
china
even
countri
strong
humantohuman
transmiss
establish
feb
case
infect
confirm
mainland
china
includ
death
prevent
control
spread
epidem
mani
strategi
need
predict
trend
epidem
quit
import
alloc
medic
resourc
arrang
product
activ
even
domest
econom
develop
china
therefor
urgent
use
latest
data
establish
effici
highli
suitabl
epidem
analysi
predict
model
accord
actual
situat
give
reliabl
predict
could
provid
import
refer
govern
formul
emerg
macroeconom
decis
medic
resourc
alloc
recent
susceptibleexposedinfectiousrecov
seir
similar
model
use
forecast
potenti
domest
intern
spread
epidem
paramet
estim
sourcesth
real
situat
could
much
complic
chang
time
especi
implement
chines
govern
multipl
epidem
control
polici
control
nationwid
epidem
becom
obviou
howev
medic
suppli
hubei
still
affect
implement
nation
polici
letter
present
current
situat
epidem
predict
ongo
trend
data
driven
analysi
estim
outbreak
size
hubei
area
mainland
china
data
epidem
list
tabl
also
graphic
shown
fig
china
use
denot
mainland
china
mainland
china
hubei
provinc
data
includ
daili
confirm
suspect
infect
total
confirm
suspect
infect
daili
death
total
death
jan
feb
report
nation
health
commiss
republ
china
nhc
health
commiss
hubei
provinc
hch
jan
contain
case
report
zeroth
day
letter
other
impli
total
number
suspect
case
reach
peak
valu
day
feb
drop
rapidli
notic
feb
almost
case
death
locat
hubei
provinc
reveal
epidem
hubei
much
seriou
area
china
hand
state
strict
quarantin
limit
popul
mobil
effect
prevent
outbreak
provinc
china
scribe
data
daili
infect
death
hubei
x
denot
day
repres
turn
point
k
paramet
determin
data
togeth
cumul
data
infect
death
obtain
integr
h
epidem
area
china
data
infect
show
asymmetr
charact
describ
x
paramet
b
k
k
togeth
determin
fit
data
fig
show
fit
trend
predict
total
infect
death
hubei
china
hubei
extract
turn
point
infect
hubei
day
name
feb
epidem
hubei
predict
end
mar
estim
epidem
end
total
infect
hubei
includ
clinic
diagnos
case
sinc
feb
may
enlarg
predict
time
consid
data
name
data
jan
feb
averag
error
bout
fit
describ
daili
cumul
infect
hubei
respect
correspond
averag
rel
error
respect
fig
b
e
show
estim
total
daili
death
hubei
predict
turn
point
feb
total
death
estim
notic
distribut
daili
death
delay
day
compar
daili
infect
averag
error
bout
model
describ
daili
cumul
death
number
respect
correspond
rel
error
respect
number
daili
total
infect
china
hubei
show
fig
c
f
respect
extract
turn
point
feb
epidem
expect
end
day
name
mar
estim
number
cumul
infect
china
tabl
data
epidem
caus
pneumonia
mainland
china
hubei
includ
daili
infect
b
daili
death
c
total
infect
total
death
e
daili
f
total
suspect
case
china
hubei
b
c
e
f
b
c
fig
f
parameter
data
henc
give
trend
predict
epidem
china
predict
end
mar
caus
infect
death
howev
data
trend
show
quick
activ
strategi
reduc
human
exposur
taken
china
limit
popul
mobil
interperson
contact
rate
strict
quarantin
migrant
alreadi
good
impact
control
epidem
outbreak
death
epidem
mainli
hubei
provinc
letter
written
hubei
report
confirm
infect
includ
clinic
diagnos
case
feb
almost
time
greater
data
previou
day
huge
fluctuat
due
chang
diagnost
criteria
hubei
clinic
criteria
taken
hubei
expect
play
activ
import
role
control
outbreak
death
rate
author
declar
conflict
interest
dear
editor
recent
sever
studi
journal
highlight
threat
avian
influenza
viru
aiv
human
poultri
anim
equin
one
report
influenza
outbreak
caus
aiv
occur
china
howev
aiv
still
pose
potenti
threat
equin
contrast
aiv
equin
influenza
viru
eiv
commonli
known
caus
pathogen
acut
respiratori
diseas
equin
date
two
subtyp
eiv
determin
equin
popul
worldwid
eiv
initi
identifi
pragu
last
outbreak
caus
eiv
occur
eiv
first
isol
miami
current
respons
ei
outbreak
worldwid
continu
transmiss
evolut
equin
eiv
strain
diverg
genet
three
distinct
lineag
prediverg
european
american
histor
four
main
ei
outbreak
mainland
china
occur
china
occur
china
occur
china
occur
first
third
fourth
outbreak
isol
eiv
strain
subtyp
subtyp
european
lineag
subtyp
american
lineag
respect
second
ei
outbreak
caus
pathogen
determin
subtyp
influenza
viru
iav
antigen
character
howev
genet
sequenc
eight
segment
genet
closer
avian
influenza
viru
eiv
indic
interspeci
transmiss
event
ei
outbreak
china
contain
two
major
outbreak
first
ei
outbreak
occur
jilin
heilongjiang
provinc
march
june
morbid
mortal
herd
second
ei
outbreak
occur
heilongjiang
provinc
april
morbid
mortal
high
mortal
uniqu
antigen
attract
attent
eiv
research
howev
ei
outbreak
china
viru
disappear
equin
popul
unknown
reason
although
evid
epidemiolog
investig
worldwid
support
continu
circul
eiv
equin
underestim
potenti
interspeci
aiv
transmiss
equin
possibl
futur
ei
outbreak
caus
aiv
haemagglutinin
ha
iav
recogn
bind
cell
surfac
sialic
acid
sa
receptor
host
respiratori
tract
viru
enter
cell
replic
distribut
sa
receptor
influenc
host
rang
iav
human
influenza
virus
preferenti
bind
gal
receptor
aiv
preferenti
bind
gal
receptor
report
gal
receptor
abund
epitheli
cell
hors
trachea
anim
experi
indic
iav
ha
recogn
gal
receptor
could
replic
hors
find
provid
prerequisit
crossspeci
transmiss
aiv
equin
fact
sever
piec
direct
molecular
evid
support
interspeci
transmiss
aiv
equin
addit
ei
outbreak
china
abdelmoneim
et
al
report
one
eiv
strain
aequineegypt
isol
donkey
cough
fever
serou
nasal
discharg
egypt
sequenc
result
indic
viru
close
genet
related
aiv
addit
seroconvers
observ
examin
donkey
collect
equin
lung
tissu
sampl
china
isol
one
aivderiv
eiv
strain
http
knscnkinet
kcmsdetaildetailaspx
dbcodecmfd
among
test
equin
serum
sampl
china
sampl
posit
antibodi
ei
outbreak
pakistan
khana
et
al
report
isol
eiv
strain
reassort
aiv
common
characterist
report
crossspeci
transmiss
event
aiv
equin
china
pakistan
egypt
occur
farm
equin
mix
farm
system
equin
domest
poultri
often
live
close
proxim
compar
racehors
farm
equin
opportun
contact
domest
poultri
experi
longterm
environment
exposur
poultri
aiv
infect
poultri
increas
exposur
risk
equin
recent
frequent
report
crossspeci
transmiss
event
aiv
farm
dog
china
korea
also
indic
potenti
threat
aiv
farm
anim
close
contact
poultri
anoth
problem
farm
equin
china
pakistan
egypt
vaccin
histori
even
racehors
popul
vaccin
eiv
routin
perform
recommend
world
organ
anim
health
oie
expert
surveil
panel
ei
vaccin
composit
although
eiv
antigen
distinct
anim
experi
indic
high
dose
ei
vaccin
still
provid
complet
protect
challeng
accordingli
routin
vaccin
ei
vaccin
equin
might
prevent
aiv
infect
degre
least
subtyp
aiv
sever
strategi
may
help
reduc
threat
aiv
equin
includ
reduc
exposur
equin
poultri
bird
host
iav
especi
anim
clinic
sign
influenza
viru
infect
monitor
aiv
preval
domest
poultri
around
equin
routin
vaccin
domest
poultri
aiv
vaccin
vaccin
suscept
equin
ei
vaccin
especi
farm
equin
close
contact
domest
poultri
monitor
preval
multipl
aiv
subtyp
equin
mere
restrict
subtyp
none
read
interest
recent
articl
journal
regard
util
nextgener
sequenc
diagnosi
bacteri
mening
bacteri
mening
caus
substanti
morbid
mortal
worldwid
rapid
identif
microorgan
essenti
earli
initi
appropri
antimicrobi
therapi
therebi
improv
clinic
outcom
yet
routin
diagnost
method
fail
identifi
bacteria
major
patient
last
decad
advanc
sequenc
technolog
greatli
improv
capac
detect
caus
agent
infecti
diseas
clinic
sampl
singl
molecul
realtim
sequenc
develop
oxford
nanopor
technolog
ont
promis
tool
diagnost
set
short
turnaround
time
late
april
old
seller
fishnoodl
refer
hospit
histori
headach
fever
vomit
histori
heavi
alcohol
use
hepat
c
infect
cirrhosi
diabet
mellitu
admiss
unconsci
glasgow
coma
scale
bodi
temperatur
blood
pressur
mmhg
neck
stiff
initi
gramstain
microscopi
csf
show
gramposit
cocci
white
cellsul
neutrophil
elev
protein
low
glucos
level
high
lactat
concentr
fig
routin
bacteri
cultur
plu
streptococcu
pneumonia
sui
pcr
neg
diagnos
bacteri
mening
given
combin
ceftriaxon
h
dexamethason
h
clinic
condit
steadili
improv
second
third
csf
sampl
becam
neg
gram
stain
csf
paramet
also
improv
except
glucos
remain
low
fig
day
hospit
patient
suddenli
becam
unconsci
fever
brain
magnet
reson
imag
show
bifront
abscess
fig
b
consult
local
neurosurgeon
aspir
brain
abscess
advis
patient
treat
empir
meropenem
h
vancomycin
h
due
continu
diagnost
uncertainti
perform
rrna
sequenc
admiss
csf
store
part
go
clinic
studi
supplementari
materi
use
establish
sangersequenc
base
rrna
method
subsequ
analysi
obtain
sequenc
reveal
evid
agalactia
supplementari
figur
given
new
diagnost
result
admiss
csf
patient
recov
clinic
patient
given
million
unit
penicillin
g
everi
h
day
hospit
csf
paramet
normalis
fig
likewis
ct
scan
brain
abscess
significantli
improv
fig
c
patient
discharg
full
clinic
recoveri
addit
minion
sequenc
complet
rrna
gene
retrospect
carri
extract
nucleic
acid
admiss
csf
yield
total
read
min
sequenc
run
read
success
align
agalactia
fig
remain
read
assign
streptococcu
speci
mostli
dysgalacticia
n
like
attribut
combin
high
level
sequenc
similar
rrna
region
sequenc
error
introduc
minion
system
analysi
sequenc
data
gener
min
sequenc
run
time
also
yield
result
supplementari
figur
detail
minion
procedur
present
supplementari
materi
assess
util
csf
minion
sequenc
rrna
gene
detect
bacteri
mening
pathogen
six
csf
sampl
patient
confirm
bacteri
mening
enrol
abovement
clinic
studi
test
tabl
analysi
minion
read
obtain
two
hour
sequenc
run
show
major
read
correctli
assign
correspond
bacteri
speci
pneumonia
sui
genu
neisseria
found
csf
sampl
diagnost
work
clinic
studi
fig
e
tabl
addit
analysi
obtain
read
gener
two
earlier
time
point
min
min
sequenc
run
gener
result
tabl
collect
report
first
applic
minion
sequenc
rrna
gene
detect
bacteri
mening
caus
pathogen
csf
sampl
low
middleincom
countri
assay
abl
detect
bacteri
caus
seven
test
csf
sampl
meanwhil
gram
stain
cultur
two
commonli
use
method
clinic
microbiolog
laboratori
worldwid
neg
sampl
fig
tabl
addit
csf
sampl
describ
present
studi
recent
pilot
studi
korea
success
detect
haemophilu
influenza
sputum
campylobact
fetu
cultur
materi
minion
sequenc
rrna
recent
report
togeth
data
suggest
minion
sequenc
rrna
sensit
method
rapid
accur
detect
panbacteri
pathogen
includ
unexpect
microorgan
clinic
sampl
addit
bacteri
speci
inform
gener
analysi
rrna
sequenc
use
diseas
surveil
vaccin
evalu
thu
applic
method
would
relev
patient
manag
epidemiolog
research
inde
best
knowledg
present
studi
repres
first
report
agalactia
associ
mening
vietnam
incid
invas
diseas
includ
mening
caus
agalactia
report
increas
frequenc
recent
year
agalactia
consid
import
differenti
owe
unavail
reagent
time
patient
admiss
abl
perform
realtim
diagnosi
use
minion
sequenc
collect
csf
sampl
howev
day
diagnosi
theoret
achiev
current
workflow
take
h
oper
prospect
studi
urgent
need
assess
translat
potenti
diagnosi
bacteri
mening
sinc
septemb
prospect
observ
studi
aim
explor
util
potenti
nextgener
sequenc
patient
present
central
nervou
system
cn
infect
conduct
brain
infect
ward
hospit
tropic
diseas
htd
ho
chi
minh
citi
vietnam
htd
tertiari
referr
hospit
patient
infecti
diseas
southern
provinc
vietnam
serv
popul
million
patient
year
indic
lumbar
punctur
elig
enrol
patient
exclud
written
inform
consent
obtain
per
studi
protocol
csf
plasma
urin
sampl
collect
present
alongsid
demograph
metaclin
data
result
routin
diagnosi
collect
clinic
specimen
store
analysi
clinic
studi
receiv
approv
institut
review
board
htd
oxford
tropic
research
ethic
committe
univers
oxford
written
inform
consent
obtain
studi
particip
rel
patient
unconsci
sequenc
complet
rrna
gene
retrospect
perform
use
minion
nanopor
sequenc
ont
follow
manufactur
instruct
brief
amplif
complet
rrna
gene
librari
prepar
carri
extract
nucleic
acid
use
barcod
kit
ont
primer
follow
sequenc
amplifi
product
use
flow
cell
ont
minion
read
first
basecal
use
albacor
ont
follow
demultiplex
use
porechop
http
githubcomrrwickporechop
determin
bacteri
genusspeci
composit
obtain
read
carri
use
interfac
metrichor
oxford
uk
platform
cloudbas
analysi
minion
data
overal
whole
procedur
minion
sequenc
rrna
gene
take
h
complet
supplementari
figur
author
submit
manuscript
declar
commerci
associ
might
pose
conflict
interest
eg
pharmaceut
stock
ownership
consult
advisori
board
membership
relev
patent
research
fund
dear
editor
sever
aspect
influenza
highlight
recent
includ
global
compar
season
issu
around
rapid
pointofcar
test
addit
uk
nation
surveil
programm
uk
sever
influenza
surveil
system
usiss
monitor
investig
sever
case
influenza
across
countri
includ
sever
case
influenza
admit
intens
care
icu
high
depend
unit
hdu
specif
aim
latter
arm
monitor
estim
impact
season
influenza
popul
describ
epidemiolog
sever
diseas
surveil
began
influenza
season
continu
present
mandatori
particip
nh
trust
leicest
one
nh
commiss
centr
uk
provid
extracorpor
membran
oxygen
ecmo
support
sever
acut
respiratori
failur
adult
process
involv
drain
deoxygen
venou
blood
superior
inferior
vena
cava
pump
blood
membran
lung
oxygen
carbon
dioxid
elimin
take
place
oxygen
blood
deliv
back
right
atrium
therefor
replac
function
nativ
lung
way
ecmo
use
support
patient
respiratori
failur
caus
accept
admiss
ecmo
support
follow
referr
ecmo
servic
via
structur
questionnair
discuss
ecmo
consult
oncal
patient
commenc
ecmo
benefit
deem
outweigh
risk
patient
potenti
revers
respiratori
failur
alreadi
maxim
convent
therapi
refer
centr
achiev
lung
protect
ventil
part
nation
usiss
role
describ
sever
influenza
case
requir
ecmo
support
predomin
indic
sever
hypoxia
pao
fio
ratio
despit
maxim
convent
therapi
andor
hypercapno
respiratori
failur
ph
despit
ventil
pressur
cm
h
influenza
season
case
sever
influenza
admit
glenfield
hospit
ecmo
refer
centr
male
year
bmi
femal
year
bmi
white
british
ethnic
chines
asian
african
ethnic
comorbid
includ
obes
hypertens
asthma
copd
diabet
anxieti
depress
epilepsi
histori
smoke
alcohol
use
abus
case
except
one
influenza
infect
possibl
two
subtyp
perform
anoth
sampl
due
influenza
one
case
histori
influenza
vaccin
variou
referr
ecmorel
paramet
extract
well
contemporan
laboratori
result
statist
compar
patient
die
n
surviv
use
test
mannwhitney
test
continu
variabl
fisherexact
test
categor
variabl
correl
durat
ecmo
laboratori
paramet
assess
use
spearman
rank
correl
coeffici
n
tabl
surprisingli
found
direct
comparison
referr
paramet
patient
start
ecmo
statist
differ
influenzainfect
patient
eventu
surviv
n
versu
die
n
case
fatal
rate
one
patient
drop
analysi
due
miss
data
respiratori
rate
rr
p
lactat
p
show
statist
signific
differ
two
group
higher
valu
found
patient
ecmo
extracorpor
membran
oxygen
sofa
sequenti
organ
failur
assess
peep
posit
end
expiratori
pressur
h
water
bpm
breath
per
minut
pao
paco
partial
pressur
arteri
oxygencarbon
dioxid
altalanin
aminotransferas
rank
correl
coeffici
measur
strength
direct
relationship
two
variabl
coeffici
rang
indic
strong
posit
relationship
two
variabl
indic
strong
neg
relationship
correl
coeffici
close
mean
relationship
two
variabl
weak
die
tabl
howev
clinic
differ
doubt
signific
rr
discret
parent
clinic
team
prior
referr
ecmo
lactat
level
normal
survivor
margin
elev
die
depend
use
cvvh
higher
pao
fio
p
f
ratio
statist
significantli
correl
p
shorter
durat
ecmo
suggest
less
sever
diseas
recov
quicker
tabl
mani
studi
report
intens
care
patient
outcom
influenza
pandem
without
use
ecmo
one
studi
australia
ecmo
use
patient
confirm
influenza
unsubtyp
infect
die
mainli
due
intracrani
form
haemorrhag
n
intract
respiratori
failur
n
anoth
studi
usa
influenza
patient
nonecmo
icu
admiss
case
develop
acut
respiratori
distress
syndrom
ard
die
recent
studi
spain
review
influenza
case
admit
icu
nonecmo
found
total
case
mortal
rang
communityacquir
influenza
hospitalacquir
influenza
ecmoicu
case
fatal
rate
sever
influenza
infect
similar
report
though
compar
specif
ecmo
patient
cohort
caus
death
patient
variabl
includ
intracrani
haemorrhag
n
sepsi
multiorgan
failur
n
respiratori
failur
n
postcardiopulmonari
resuscit
hypox
brain
injuri
n
ischaem
bowel
associ
atrial
fibril
n
thu
even
year
experi
new
pandem
influenza
viru
across
almost
entir
adult
agerang
year
previou
studi
appear
sever
case
global
surviv
patient
appear
improv
may
somewhat
surpris
world
popul
becom
immunolog
experienc
viru
consid
season
influenza
viru
confer
degre
persist
crossreact
individu
herd
immun
consecut
season
may
due
predispos
genet
environment
factor
individu
patient
reinforc
gener
messag
season
influenza
immunis
still
recommend
minimis
number
peopl
need
icu
ecmo
support
sever
influenza
infect
detail
monitor
physiolog
paramet
chang
time
perhap
includ
complex
cytokin
studi
sever
ill
influenza
patient
admit
icuecmo
unit
may
eventu
yield
data
improv
manag
clinic
outcom
none
read
interest
report
stalenhoef
colleagu
journal
show
biomark
guid
triag
reduc
hospit
rate
commun
acquir
febril
urinari
tract
infect
ref
report
prospect
observ
analysi
biomark
antigen
like
protein
serum
sampl
collect
patient
diagnos
pneumonia
healthi
adult
demograph
clinic
characterist
adult
male
mean
age
year
pneumonia
summar
tabl
bacteri
pneumonia
patient
includ
patient
confirm
bacteri
pneumonia
patient
suspect
bacteri
pneumonia
viral
pneumonia
patient
studi
signific
differ
age
sex
wbc
neu
crp
pct
apach
ii
score
length
icu
stay
bacteri
pneumonia
viral
pneumonia
pathogen
respons
pneumonia
describ
supplementari
tabl
global
gramneg
bacteria
infect
common
gramposit
bacteria
infect
pneumonia
among
acinetobact
baumannii
consid
major
pathogen
gramneg
bacteria
staphylococcu
aureu
consid
major
pathogen
gramposit
bacteria
viral
pneumonia
influenza
detect
uniqu
pathogen
studi
diagnost
perform
serum
identifi
etiolog
pneumonia
found
supplementari
fig
matter
total
bacteri
pneumonia
suspect
bacteri
pneumonia
confirm
bacteri
pneumonia
serum
level
day
pneumonia
diagnosi
significantli
higher
viral
pneumonia
healthi
control
subject
evalu
diagnost
perform
differenti
bacteri
viral
infect
pneumonia
roc
analysi
conduct
bacteri
pneumonia
supplementari
fig
compar
routin
laboratori
marker
tabl
horizont
comparison
found
best
auc
auc
better
neu
auc
wbc
auc
crp
auc
even
pct
auc
interestingli
longitudin
comparison
auc
observ
highest
confirm
bacteri
pneumonia
auc
intermedi
bacteri
pneumonia
auc
lowest
suspect
bacteri
pneumonia
auc
may
better
elucid
diagnost
perform
etiolog
diagnosi
pneumonia
patient
although
patient
suspect
bacteri
pneumonia
definit
pathogen
found
result
may
still
provid
new
treatment
bacteri
infect
identif
pneumonia
patient
current
limit
direct
pathogen
test
make
difficult
identifi
pathogen
time
diagnosi
besid
potenti
biomark
distinguish
pathogen
level
also
significantli
correl
wbc
neu
crp
pct
supplementari
fig
patient
pneumonia
studi
diagnost
perform
serum
predict
mortal
adult
pneumonia
mortal
defin
death
occur
within
day
onset
pneumonia
observ
supplementari
fig
serum
level
day
pneumonia
diagnosi
significantli
higher
nonsurvivor
n
survivor
n
p
ensur
serum
level
influenc
class
infect
specimen
spearman
rank
correl
analysi
perform
serum
level
poor
prognosi
relat
score
sofa
apach
ii
score
patient
total
bacteri
pneumonia
suspect
bacteri
pneumonia
confirm
bacteri
pneumonia
viral
pneumonia
respect
correl
analysi
serum
level
sofa
apach
ii
score
show
matter
bacteri
pneumonia
viral
pneumonia
level
show
posit
correl
sofa
apach
ii
score
supplementari
fig
furthermor
auc
identifi
mortal
adult
pneumonia
patient
supplementari
fig
valu
mean
good
diagnost
perform
consist
gao
studi
therefor
found
determin
serum
concentr
day
pneumonia
diagnosi
great
valu
identifi
bacteri
infect
viral
infect
predict
mortal
adult
patient
pneumonia
suggest
may
work
etiolog
diagnosi
could
repres
novel
biomark
identif
group
patient
pneumonia
present
higher
risk
death
find
encourag
effort
aim
explor
clinic
valu
circul
help
earli
clinic
decisionmak
human
pneumonia
none
high
morbid
mortal
asf
devast
threat
pig
agricultur
respons
seriou
product
econom
loss
asfv
genom
kilo
base
pair
length
divid
differ
genotyp
base
gene
sequenc
gene
encod
capsid
protein
previou
studi
show
gene
locat
low
genet
divers
region
genom
ye
colleagu
howev
identifi
two
novel
genotyp
xxv
xxvi
genotyp
xxvi
especi
diverg
genotyp
examin
unexpect
result
studi
reanalyz
data
evalu
reliabl
two
genotyp
collect
avail
gene
sequenc
ncbi
http
wwwncbinlmnihgov
align
mafft
softwar
fast
multipl
sequenc
align
program
align
show
genotyp
xxv
access
number
singl
amino
acid
chang
posit
compar
genotyp
genotyp
xxvi
access
number
region
code
amino
acid
residu
differ
greatli
compar
genotyp
fig
examin
greater
detail
calcul
genet
distanc
across
code
sequenc
bp
slide
window
step
size
bp
two
sequenc
genotyp
fig
b
slide
window
analysi
show
two
sequenc
genotyp
xxvi
region
diverg
genet
distanc
genotyp
genet
distanc
remain
region
less
fig
b
genet
distanc
asfv
calcul
code
gene
sequenc
avail
complet
genom
asfv
assess
overal
diverg
pairwis
genet
distanc
gene
asfv
strain
calcul
mean
pairwis
genet
distanc
asfv
gene
fig
much
lower
diverg
region
two
sequenc
genotyp
xxvi
therefor
seem
highli
unlik
gene
highli
diverg
region
sinc
recombin
frequent
occur
asfv
conduct
recombin
analysi
program
use
bootscan
chimaera
genecov
lard
maxchi
rdp
siscan
detect
method
determin
whether
recombin
might
occur
xxvi
genotyp
found
reliabl
evid
recombin
event
genotyp
xxvi
sequenc
fig
c
suggest
highli
diverg
region
genotyp
homolog
genotyp
use
blastn
ncbi
http
blastncbinlmnihgovblastcgi
identifi
sourc
highli
diverg
region
howev
similar
sequenc
found
map
multipl
amino
acid
chang
found
genotyp
xxvi
structur
fig
chang
site
mark
red
fig
locat
dec
loop
region
play
import
role
format
trimer
spike
amino
acid
mutat
result
chang
electrostat
potenti
hydrophob
steric
hindranc
seem
unlik
mani
chang
function
import
region
previou
studi
notic
sequenc
directli
submit
individu
laboratori
genbank
often
contain
error
misidentif
speci
sampl
error
contamin
pseudogen
lead
sequenc
analysi
problem
erron
conclus
sequenc
deviat
overal
intraspecif
pairwis
diverg
potenti
erron
sinc
genotyp
xxvi
deviat
genotyp
genet
distanc
also
protein
structur
mutat
occur
flank
region
sequenc
deduc
report
mutat
might
due
low
qualiti
sequenc
identifi
origin
manuscript
report
three
sequenc
genotyp
xxv
xxvi
author
state
align
translat
sequenc
obtain
sardinian
isol
reveal
ctermin
end
gene
complet
conserv
sequenc
compar
statement
indic
sequenc
consider
diverg
previous
report
asfv
sequenc
thu
suggest
error
sequenc
introduc
upon
submit
genbank
examin
origin
sampl
sequenc
need
contact
correspond
author
manuscript
check
three
sequenc
told
three
sequenc
genotyp
error
submit
genbank
conclus
two
novel
genotyp
asfv
xxv
xxvi
identifi
ye
colleagu
misl
problemat
sequenc
remind
previou
studi
mani
problemat
sequenc
present
genbank
lead
problem
downstream
analys
thu
publish
data
use
new
analys
first
set
process
data
analys
filter
sequenc
potenti
error
reduc
possibl
reach
incorrect
conclus
conclus
base
obvious
strang
sequenc
trace
back
data
origin
sourc
manuscript
contact
correspond
author
make
conclus
base
sequenc
author
declar
conflict
interest
fig
analys
phylogenet
tree
recombin
nucleotid
diverg
known
subtyp
base
fulllength
hbv
genom
sequenc
known
hcv
subtyp
refer
sequenc
previou
report
use
phylogenet
analysi
perform
maximumlikelihood
method
base
gtr
g
substitut
model
bootstrap
replic
use
softwar
mega
sequenc
hcv
mark
red
dot
b
bootscan
plot
construct
use
simplot
softwar
base
replic
slide
window
move
step
base
c
pairwis
comparison
nucleotid
similar
hcv
strain
refer
genotyp
sequenc
death
per
year
current
daa
treatment
regimen
target
proteas
phosphorprotein
polymeras
shown
high
safe
high
rate
sustain
virolog
respons
hcv
chronic
infect
patient
howev
select
pressur
drug
drug
resistanceassoci
substitut
ra
emerg
therapi
result
treatment
failur
patient
therefor
hcv
infect
still
major
global
health
concern
date
eight
confirm
genotyp
character
base
sequenc
diverg
complet
hcv
genom
genotyp
classifi
subtyp
sequenc
diverg
subtyp
genotyp
current
studi
character
new
hcv
subtyp
among
chronic
hepat
c
patient
yunnan
china
initi
design
analyz
evolutionari
histori
investig
baselin
ra
next
gener
sequenc
ng
method
plasma
sampl
collect
januari
octob
chronic
hepat
c
patient
kunm
citi
yunnan
china
fig
sampl
met
follow
inclus
criteria
hepat
c
antibodyposit
month
normal
serum
alanin
aminotransferas
alt
level
subject
resid
yunnan
provinc
year
old
complet
demograph
inform
clinic
data
avail
consent
use
patient
inform
studi
hcv
epidem
sampl
epidemiolog
link
among
individu
studi
approv
first
peopl
hospit
yunnan
provinc
ethic
committe
written
inform
consent
obtain
particip
prior
studi
total
chronic
hepat
c
patient
partial
gene
fragment
success
amplifi
sequenc
success
rate
multipl
subtyp
identifi
subject
includ
subtyp
fig
interestingli
remain
two
strain
involv
togeth
isol
report
form
novel
separ
cluster
genotyp
bootstrap
valu
indic
potenti
new
hcv
subtyp
confirm
two
strain
belong
novel
hcv
subtyp
complet
genom
sequenc
success
amplifi
sequenc
overlap
fragment
phylogenet
analysi
perform
along
hcv
refer
sequenc
repres
subtyp
result
show
two
strain
isol
form
distinct
monophylet
cluster
support
high
bootstrap
valu
three
strain
isol
three
infect
patient
without
obviou
epidemiolog
linkag
yunnan
show
evid
recombin
use
bootscan
analysi
fig
b
moreov
intergroup
nucleotid
diverg
mean
sd
fulllength
genom
sequenc
isol
compar
repres
subtyp
fig
c
result
reveal
three
strain
differ
known
hcv
subtyp
therefor
three
strain
initi
design
better
understand
time
emerg
hcv
perform
bayesian
molecular
clock
analys
use
fulllength
genom
sequenc
estim
time
recent
common
ancestor
tmrca
shown
fig
estim
tmrca
genotyp
highest
probabl
densiti
hpd
addit
investig
baselin
ra
subtyp
natur
occur
resistanceassoci
substitut
ra
analyz
sequenc
use
next
gener
sequenc
ng
method
strikingli
hcv
strain
contain
substitut
v
frequenc
mutat
protein
contribut
resist
velpatasvir
phosphoprotein
inhibitor
suggest
subtyp
mayb
basic
resist
inhibitor
fig
b
among
hcv
eight
genotyp
genotyp
exhibit
high
degre
genet
complex
divers
subtyp
confirm
intern
committe
taxonomi
virus
china
hcv
genotyp
common
subtyp
preval
subtyp
primarili
distribut
guangdong
second
preval
subtyp
mainli
found
yunnan
follow
subtyp
g
w
among
genotyp
isol
knowledg
eighth
detect
novel
hcv
subtyp
china
combin
previous
identifi
result
genotyp
expand
subtyp
world
find
demonstr
hcv
genotyp
complex
divers
summari
character
new
hcv
subtyp
base
characterist
monophylet
cluster
genet
distanc
signific
evid
recombin
epidemiolog
link
among
individu
addit
bayesian
analys
show
may
origin
around
year
strain
hcv
natur
contain
substitut
v
protein
contribut
resist
velpatasvir
phosphoprotein
inhibitor
present
find
highlight
genet
characterist
hcv
strain
yunnan
urgent
need
continu
molecular
screen
epidem
surveil
yunnan
implement
effect
measur
reduc
hcv
transmiss
author
declar
compet
financi
interest
recent
read
articl
et
al
author
describ
higher
probabl
relaps
sofosbuvirledipasvir
week
compar
week
hcv
hepat
c
viru
among
hiv
human
immunodefici
viru
hcv
coinfect
patient
regard
coinfect
hiv
hcv
also
hepat
b
viru
hbv
associ
high
mortal
comorbid
persist
hbv
dna
within
core
cell
absenc
hbsag
even
clearanc
infect
describ
previous
immunosuppress
patient
hbv
screen
prophylaxi
recommend
interestingli
hbv
reactiv
recent
emerg
hcv
treatment
directact
antivir
daa
us
food
drug
administr
issu
warn
risk
moment
case
report
two
die
although
specif
mechan
event
well
known
suggest
hcv
core
protein
could
inhibit
hbv
replic
hbsag
product
well
product
envelop
protein
hbcab
marker
presenc
hbv
context
treatment
daa
would
produc
drastic
rapidli
block
hcv
replic
provid
opportun
hbv
emerg
produc
immun
reconstitut
syndrom
interfer
hbvhcv
outlin
patient
chronic
hbv
infect
hbsagposit
serolog
patient
resolv
hbv
infect
hbsagneg
hbcabposit
recent
publish
systemat
review
metaanalysi
patient
hcvhbv
case
report
focus
coinfect
hcvhbv
still
concern
patient
tripleinfect
hcv
hbv
hiv
although
case
report
occur
hbsagposit
main
concern
affect
patient
basal
serolog
show
hbcabposit
hbsagneg
hbsabneg
hbsagposit
associ
higher
rate
hbv
reactiv
compar
hbsagneg
hbcabposit
patient
clear
inform
issu
hbsagneg
hbcabposit
occur
consid
uncommon
event
reactiv
hbv
character
reappear
increas
hbv
dna
level
could
also
accompani
symptom
hepat
case
report
previous
show
differ
time
present
clinic
symptom
use
start
either
daa
treatment
seem
hbv
reactiv
usual
occur
earli
daa
initi
treatment
week
otherwis
occur
treatment
complet
way
seem
necessari
hbv
infect
monitor
earli
daa
initi
recent
european
associ
studi
liver
easl
guidelin
hbv
infect
recommend
patient
hbsagneg
hbcabposit
undergo
daa
treatment
monitor
test
hbv
reactiv
case
alt
elev
also
recommend
perform
hbv
dna
level
case
alt
increas
time
american
associ
studi
liver
diseas
aasld
infecti
diseas
societi
america
idsa
guidelin
recent
updat
recommend
monitor
hbv
dna
level
patient
hbsagposit
emphas
enough
data
monitor
dna
among
patient
hbcabposit
hbcabposit
hbsabposit
remark
reactiv
consid
unexplain
increas
liver
enzym
present
hiv
patient
provid
recommend
recent
review
literatur
author
also
recommend
perform
hbv
dna
patient
alter
alt
metaanalysi
recommend
perform
hbv
dna
test
case
due
low
rate
incid
associ
cost
need
consid
especi
endem
hbv
area
data
exist
hiv
patient
fact
mani
tripleinfect
patient
receiv
antiretrovir
therapi
includ
art
nucleosidenucleotid
analog
tenofovir
disoproxil
fumar
tdf
tenofovir
alafenamid
taf
activ
hbv
suggest
hbv
reactiv
rate
could
underestim
recent
publish
review
chang
et
al
recommend
perform
hbv
dna
test
baselin
tripleinfect
patient
posit
hbvactiv
antiretrovir
therapi
art
start
hbv
dna
need
monitor
everi
week
treatment
week
complet
treatment
howev
baselin
hbv
dna
neg
match
aasldidsa
easl
recommend
one
patient
basal
serolog
hbcabiggposit
hbsagand
hbsabneg
undetect
hbv
dna
level
prior
treatment
daa
regard
hiv
infect
analoguesfre
regimen
one
month
finish
treatment
daa
patient
consult
abdomin
pain
nausea
jaundic
total
bilirubin
level
mgdl
ast
iul
alt
iul
inr
hbv
viral
load
iuml
detect
hbsag
hbcabigm
hbeag
posit
reason
believ
reinfect
treatment
entecavir
initi
howev
clinic
evolut
unfavor
die
result
acut
liver
failur
hbv
viral
load
request
store
sampl
drawn
treatment
hcv
show
hbv
viral
load
undetect
begin
treatment
week
progress
increas
iuml
week
iuml
week
treatment
complet
followup
daa
treatment
alt
ast
remain
normal
case
chang
daili
practic
sinc
hiv
patient
specif
treat
either
tdf
taf
present
previou
hbcabposit
follow
use
dna
level
monitor
hepat
enzym
recommend
guidelin
consid
case
may
reflect
necess
chang
current
guidelin
recommend
perform
period
monitor
hbv
reactiv
use
hbv
dna
daa
therapi
hbsagneg
hbcabposit
patient
independ
hbsab
presenc
hepat
enzym
clinic
symptom
particularli
hiv
patient
receiv
activ
treatment
hbv
studi
fund
author
declar
conflict
interest
recent
notabl
pattern
synchroni
influenza
b
viru
respiratori
syncyti
viru
incid
peak
global
report
journal
previou
studi
character
season
pattern
influenza
b
china
identifi
three
epidemiolog
region
featur
distinct
season
basi
laboratori
surveil
data
chines
provinc
span
year
octob
januari
studi
character
season
pattern
circul
influenza
subtyp
influenza
b
lineag
three
defin
epidemiolog
region
studi
reveal
display
wintertim
summertim
epidem
midlatitud
southernmost
chines
provinc
subtrop
climat
wavelet
analysi
demonstr
two
subtyp
display
twiceannu
cycl
year
midlatitud
chines
provinc
fig
h
howev
two
subtyp
peak
winter
annual
longer
cycl
northern
chines
provinc
influenza
bvictoria
byamagata
viru
display
epidem
winter
winterspr
annual
longer
cycl
three
epidemiolog
region
develop
univari
multivari
regress
model
evalu
associ
climat
factor
presenc
absenc
epidem
influenza
subtyp
lineag
posit
proport
southernmost
provinc
heat
system
gener
use
winter
temperatur
rel
humid
extern
condit
winter
close
indoor
environ
peopl
spend
time
fit
mixedeffect
logist
regress
model
control
repeat
measur
provinc
region
cluster
kept
one
temperatur
absolut
humid
repres
vapor
pressur
smaller
akaik
inform
criterion
model
reduc
multicollinear
due
high
degre
correl
two
factor
analysi
indic
temperatur
humid
rainfal
environment
predictor
influenza
subtypelineagespecif
epidem
southernmost
provinc
lag
influenza
epidem
behind
climat
consid
similar
find
ecolog
studi
tabl
studi
indic
ushap
relationship
absolut
humid
ah
epidem
southernmost
provinc
suggest
high
level
ah
summer
low
level
ah
winter
increas
possibl
epidem
two
subtyp
analysi
lower
temperatur
environment
driver
byamagata
epidem
southernmost
provinc
bimod
associ
temperatur
rainfal
bvictoria
epidem
highest
probabl
bvictoria
epidem
daili
averag
temperatur
mm
daili
averag
rainfal
although
season
chang
human
behavior
school
attend
crowd
indoor
season
variat
immun
melatonin
vitamin
level
propos
account
season
natur
influenza
find
suggest
heterogen
influenza
subtypelineagespecif
season
pattern
could
driven
season
variat
viru
surviv
transmiss
adapt
immun
influenza
subtyp
lineag
behavior
mode
background
nonadapt
immun
region
season
propos
hypothesi
humid
hot
condit
domin
transmiss
mode
bvictoria
byamagata
might
reduc
effici
howev
could
effect
transmiss
mode
viru
experiment
studi
perform
establish
causal
link
humid
temperatur
influenza
viru
survivaltransmiss
transmiss
influenza
bvictoria
byamagata
viru
respiratori
droplet
aerosol
guinea
pig
model
proce
readili
cold
dri
condit
low
humid
temperatur
increas
stabil
influenza
viru
aerosol
surfac
furthermor
aerosol
transmiss
viru
guinea
pig
model
almost
complet
block
contact
transmiss
viru
seem
effici
differ
level
humid
remain
unclear
high
temperatur
humid
level
effect
aerosol
contact
transmiss
bvictoria
byamagata
viru
among
host
stabil
surfac
note
experiment
studi
found
surviv
durat
strain
swiss
banknot
significantli
longer
bvictoria
viru
studi
need
understand
effici
transmiss
mode
differ
influenza
subtyp
lineag
isar
domin
mode
transmiss
among
host
potenti
mechan
play
humid
hot
condit
one
find
mutual
invers
associ
epidem
provid
evid
interfer
two
influenza
subtyp
perhap
possibl
due
multipl
immun
mechan
howev
studi
show
byamagata
epidem
posit
correl
epidem
suggest
byamagata
epidem
across
studi
year
weak
could
get
well
along
simultan
weak
epidem
understand
influenza
season
import
defin
optim
time
influenza
vaccin
campaign
studi
indic
viru
brought
twiceannu
epidem
year
midlatitud
chines
provinc
frequent
summertim
epidem
southernmost
chines
provinc
question
singl
annual
influenza
vaccin
campaign
start
octob
offer
optim
protect
summertim
epidem
viru
midlatitud
southernmost
chines
provinc
recent
year
report
mismatch
viru
influenza
vaccin
strain
circul
strain
identifi
frequent
vaccin
effect
viru
declin
within
month
postvaccin
conclus
identifi
heterogen
season
pattern
viru
three
epidemiolog
region
china
differ
environ
predictor
influenza
subtyp
lineag
southernmost
provinc
work
focu
understand
differ
viru
surviv
transmiss
influenza
subtyp
lineag
humid
hot
condit
bjc
receiv
research
fund
medimmun
inc
sanofi
pasteur
consult
crucel
nv
author
report
potenti
compet
interest
studi
includ
data
nation
influenza
surveil
system
ethic
approv
requir
applic
dataset
nation
level
analyz
current
studi
avail
world
health
organ
flunet
dataset
specif
inform
analyz
current
studi
avail
chines
nation
influenza
surveil
informatio
system
openaccess
dataset
influenza
surveil
data
avail
chines
nation
influenza
center
reason
request
studi
support
nation
megaproject
infecti
diseas
grant
number
nation
natur
scienc
foundat
china
grant
number
emerg
prevent
control
project
ministri
scienc
technolog
grant
number
fund
bodi
role
studi
design
data
collect
analysi
prepar
manuscript
decis
publish
report
zhejiang
studi
identifi
ten
case
import
chikv
infect
travel
return
yunnan
southeastern
asia
ten
patient
import
chikv
infect
examin
studi
nine
patient
travel
back
myanmar
one
patient
travel
back
thailand
fig
patient
display
differ
degre
symptom
fever
cough
muscl
pain
rash
detail
symptom
shown
tabl
chikv
infect
diagnos
use
specif
realtim
revers
transcriptionpcr
serum
specimen
collect
ten
patient
test
posit
chikv
realtim
pcr
analysi
yunnan
may
august
current
studi
approv
medic
ethic
committe
kunm
univers
scienc
technolog
written
inform
consent
obtain
particip
